What are the pharmacologic effects, dosing regimen, and adverse effect profile of cefepime (fourth‑generation cephalosporin) when used as a single agent in an adult with normal renal function?

Cefepime: Pharmacologic Effects, Dosing, and Adverse Effects

Cefepime is a fourth-generation cephalosporin with broad-spectrum activity against both Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa, dosed at 1-2 g IV every 8-12 hours in adults with normal renal function, with the most critical adverse effect being neurotoxicity that can occur even with normal kidney function.

Antimicrobial Spectrum and Mechanism

Cefepime exhibits a unique dual spectrum of activity:

• Gram-positive coverage comparable to cefotaxime, including penicillin-susceptible, -intermediate, and -resistant Streptococcus pneumoniae and methicillin-susceptible Staphylococcus aureus 1, 2
• Gram-negative coverage similar to ceftazidime, with excellent activity against Pseudomonas aeruginosa and Enterobacteriaceae 1, 2
• Enhanced stability against AmpC β-lactamases and many plasmid-mediated β-lactamases, making it effective against organisms resistant to third-generation cephalosporins, particularly derepressed mutants of Enterobacter species 3

The drug's zwitterionic configuration allows rapid penetration through bacterial outer-membrane porin channels, while its structural features provide low affinity for β-lactamases 4, 5. Cefepime exerts bactericidal effects by binding to penicillin-binding proteins and disrupting cell wall synthesis 5.

Important limitations: Cefepime lacks activity against Enterococcus faecalis, Clostridium difficile, methicillin-resistant S. aureus, and Bacteroides species 6, 5.

Standard Dosing Regimens (Normal Renal Function)

According to FDA labeling and clinical guidelines 7, 1, 2:

Adults

• Moderate infections (UTI, pneumonia): 1-2 g IV every 12 hours
• Severe infections (nosocomial pneumonia, sepsis): 2 g IV every 8-12 hours
• Febrile neutropenia: 2 g IV every 8 hours
• Complicated intra-abdominal infections: 2 g IV every 8-12 hours (with metronidazole)

Pediatric Patients (2 months to 16 years, ≤40 kg)

• Standard infections: 50 mg/kg every 12 hours
• Severe pneumonia or febrile neutropenia: 50 mg/kg every 8 hours
• Maximum dose should not exceed adult dosing 7

Administration

Administer as 30-minute IV infusion 7. Recent evidence suggests continuous infusion of 4 g/day (after 2 g loading dose) may optimize pharmacodynamic target attainment while reducing neurotoxicity risk 8.

Critical Adverse Effect: Neurotoxicity

The most clinically significant adverse effect is cefepime-induced neurotoxicity (CIN), which has a relative pro-convulsive activity of 160 (compared to penicillin G = 100), second only to cefazolin among β-lactams 9.

Neurotoxicity Risk Factors and Thresholds

While renal impairment is the primary risk factor, neurotoxicity can occur in patients with normal renal function 10, 11:

• Trough concentrations >22 mg/L (intermittent dosing) or steady-state >35 mg/L (continuous infusion) associated with 50% neurotoxicity risk 9
• Neurotoxicity occurred in 48% of overexposed patients but also in 26% of appropriately dosed patients with normal renal function 9
• Target concentration should not exceed 8× MIC to optimize benefit-risk ratio 9

Clinical Presentation

Symptoms typically appear 2-6 days after initiation 11:

• Confusion, delirium, altered mental status
• Drowsiness, stupor, or coma
• Myoclonus
• Seizures (though rare in comparative trials: 0% with cefepime vs 0.07% with ceftazidime) 12
• Encephalopathy

High-Risk Populations

• Age >65 years (21% fewer delirium/coma-free days vs piperacillin-tazobactam) 13
• Renal function deterioration during therapy 8
• Pre-existing neurological conditions 9
• Brain injury or severe trauma patients 14
• Patients with creatinine clearance 60-90 mL/min receiving high-dose regimens 14

Critical pitfall: Even patients with augmented renal clearance (>150 mL/min) can experience overexposure, particularly if age >33 years 14.

Other Adverse Effects

Based on comparative trials with 2,032 cefepime-treated patients 12:

Common (>1%)

• Headache (2.4%)
• Rash (1.8%)
• Nausea (1.8%)
• Diarrhea (1.7%)

Laboratory Abnormalities

• Positive Coombs' test: 14.5% with high-dose cefepime vs 8.7% with ceftazidime, though no hemolysis observed 12

Rare but Serious

• Anaphylaxis (0% in comparative trials) 12
• Gastrointestinal hemorrhage (not drug-related in reported cases) 12
• Renal toxicity (rare) 12

The overall adverse event rate (13.8%) is comparable to ceftazidime (15.6%), with an excellent safety profile when appropriately dosed 12.

Monitoring and Prevention Strategies

To prevent neurotoxicity:

1. Therapeutic drug monitoring (TDM) within 24-48 hours of initiation, especially in:

   • Patients >65 years
   • Any degree of renal impairment
   • High-dose regimens (≥6 g/day)
   • Critically ill patients 8, 14

2. Target plasma concentrations: Maintain free cefepime 4-8× MIC, avoiding >8× MIC 9

3. Consider dose reduction: 4 g/day continuous infusion achieves 96% target attainment for Enterobacteriaceae and 93% for P. aeruginosa with only 6.5% neurotoxicity rate 8

4. Immediate discontinuation if unexplained neurological symptoms develop 9

Clinical Efficacy Context

Despite neurotoxicity concerns, cefepime remains highly effective with 96% clinical efficacy in real-world studies 8. However, given the mortality signal from meta-analyses and the ACORN trial findings, cefepime has been relegated to "preserved" status in WHO guidelines, recommended only when other options are inappropriate 15.

When cefepime is necessary: Use the lowest effective dose, implement early TDM, and maintain heightened vigilance for neurological changes, particularly in older adults and those with any renal compromise.